secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2022-09-02T23:59:59+00:00
Accession:  0001753926-22-001222
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani (fka Second Sight) completes merger with Nano Precision Medical; ticker changes to VANI
--------------------------------------------------------------------------------

- Closed merger with NPM on Aug 30, 2022; issued 37.6M shares to NPM holders, giving them ~74.1% ownership.
- Name changed to Vivani Medical; common stock begins trading under VANI; warrants VANIW to be delisted.
- Board reduced to five; Adam Mendelsohn appointed CEO; new C-suite includes Brigid Makes (CFO), Truc Le (COO).
- Pro forma cash ~$55M; lead drug implant NPM-119 for Type 2 diabetes expected to begin clinical evaluation by end of 2022.
- NPM's unaudited H1 2022 net loss $8.0M on zero revenue; cash and equivalents $3.45M as of June 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392622001222/0001753926-22-001222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392622001222/g083173_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-22-001222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer